8 min listen
Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema
Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema
ratings:
Length:
13 minutes
Released:
Feb 2, 2023
Format:
Podcast episode
Description
Interview with David W. Hutton, PhD, author of Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. Hosted by Neil Bressler, MD.
Released:
Feb 2, 2023
Format:
Podcast episode
Titles in the series (100)
Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations: Safety and Efficacy in 15 Children and Adults Followed Up to 3 Years: Interview with Samuel G. Jacobson, MD, PhD, author of Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations: Safety and Efficacy in 15 Children and Adults Followed Up to 3 Years by JAMA Ophthalmology Author Interviews